Research Data on BPC-157 TB-500 and Their Combination

This page collects the published research on BPC-157 and TB-500 into a single reference. The study tables below list species, model, route, dose, duration, primary outcome and PubMed ID for each cited paper. The goal is to provide a transparent, verifiable resource that links directly to the primary literature. All data is from animal or in-vitro studies unless explicitly stated otherwise. This page also addresses the critical question of whether any study has tested BPC-157 and TB-500 in combination.

BPC-157 Research Overview

Number of Published Studies

BPC-157 has been the subject of peer-reviewed research since the early 1990s. The body of literature includes studies on gastrointestinal protection, tendon and ligament healing, muscle repair, nerve regeneration, wound healing and vascular function. The majority of publications originate from a single research group at the University of Zagreb in Croatia, led by Predrag Sikiric. This concentration of authorship is worth noting because independent replication by other laboratories remains limited for many endpoints.

Over 100 peer-reviewed papers have been published on BPC-157 across all endpoints. The number of studies testing musculoskeletal endpoints specifically is smaller, approximately 15-20 papers. Gastrointestinal studies represent the largest single category.

Primary Research Areas

The research divides into several categories: gastrointestinal protection (ethanol, NSAID, stress-induced gastric lesions), musculoskeletal repair (tendon, ligament, muscle), neurological effects (nerve crush, dopaminergic interactions), wound healing (dermal, corneal), vascular function (nitric oxide modulation, blood pressure) and organ protection (liver, kidney). The breadth is notable, though the depth of evidence varies significantly by area. Gut protection has the most consistent replication. Tendon studies are the most mechanically rigorous. Many other areas have only one or two published papers.

Complete BPC-157 Study Table

When we review the BPC-157 data, several patterns stand out. The dose of 10 mcg/kg is used in the majority of rat studies, administered once daily via intraperitoneal injection. The observation period is most often 14 days. Biomechanical testing (load to failure, stiffness) is used in tendon studies, while histological grading and functional assessments appear in muscle and wound studies. The consistency of dosing and methodology across studies reflects the fact that most originate from the same laboratory. For broader context on how these peptides compare, see our stacking benefits overview.

TB-500 Research Overview

Number of Published Studies

Thymosin Beta-4 (the parent protein of TB-500) has a substantial research history in cell biology, dating back to its identification as a major actin-sequestering protein. However, the number of studies testing TB-4 or TB-500 in whole-animal injury models is considerably smaller than the BPC-157 literature. An estimated 30-50 peer-reviewed papers have tested TB-4 in animal injury or healing models. The research base is distributed across multiple laboratories and countries, which provides better independent replication than BPC-157.

Primary Research Areas

TB-4 research concentrates on wound healing (dermal, corneal), cardiac repair (post-myocardial infarction), inflammation and neurological recovery. The cardiac data is particularly well-developed, with studies from multiple independent groups showing reduced scar tissue and improved cardiac function in mouse models. Dermal wound healing studies show accelerated closure mediated by enhanced cell migration. Corneal wound studies demonstrate faster re-epithelialization.

Complete TB-500 Study Table

The TB-500 research base is smaller than BPC-157's but, as we noted above, benefits from contributions by multiple independent laboratories. The cardiac studies by Bock-Marquette and the wound healing studies by Malinda represent distinct research programs, providing a degree of independent validation that BPC-157 studies currently lack. Dosing in TB-4 studies is less uniform, with some studies using weight-based dosing and others using fixed doses per animal.

Combination Studies - BPC-157 and TB-500 Together

How Many Studies Test Both

As of the time this page was compiled, one published study was identified that tested BPC-157 and TB-500 in the same experiment. A 2025 study compared BPC-157 alone, TB-500 alone and their combination in a rat Achilles tendon transection model. Both peptides individually improved healing markers over saline controls. The combination group did not show statistically superior results to either peptide alone across all endpoints measured. This is a single study in one tissue type in rats, and the results need independent replication.

Outside of this one paper, no published study testing BPC-157 and TB-500 together was found in any animal model for any endpoint. The combination is widely discussed in online forums and sold as a pre-mixed blend by some vendors, but the research foundation for combining these two peptides consists of a single preclinical experiment.

Why the Gap Exists

The lack of combination studies reflects several realities of peptide research. BPC-157 and TB-500 were developed by different research groups studying different biological questions. The Zagreb group focused on gastric protection and tissue repair mechanisms. TB-4 researchers concentrated on actin biology, wound healing and cardiac repair. These research programs operated independently, and the idea of combining the peptides originated in the consumer market, not in the laboratory.

Academic research funding does not typically support testing popular supplement combinations. The "stack" concept comes from bodybuilding culture, where combining compounds is standard practice, and the research community has not prioritized validating these consumer-driven protocols. We expect this gap to persist because the commercial interest in the combination exceeds the scientific interest.

Research Methodology Notes

Common Study Designs

The standard design in both BPC-157 and TB-500 research is a controlled animal experiment. Researchers create a standardized injury (surgical transection, crush, chemical lesion, surgical ligation), treat one group with the peptide and another with saline, then measure outcomes at predetermined time points. Sample sizes are typically small (8-12 animals per group). Blinding varies by study, with some reporting blinded outcome assessment and others not specifying.

Outcome measures include histological grading (tissue appearance under microscope), biomechanical testing (tensile strength, load to failure), immunohistochemistry (protein expression in tissue), functional testing (gait analysis, grip strength) and gross morphology (wound area, scar size). The most rigorous studies combine multiple outcome types. Studies using only histological grading are more susceptible to observer bias than those including mechanical or functional measures.

Limitations of Preclinical Peptide Research

Several limitations apply broadly across both peptide research bases. Small sample sizes reduce statistical power and increase the chance of false positives. Short observation periods (often 14 days) leave long-term outcomes unknown. Single-laboratory dominance in BPC-157 research means many findings await independent replication. Animal models do not capture the full complexity of human tissue biomechanics, immune responses or pharmacokinetics. And critically, the leap from "statistically significant improvement in a rat model" to "clinically meaningful benefit in a human patient" involves assumptions that have not been tested.

Publication bias likely affects this literature as well. Studies showing positive results are more likely to be published than those showing no effect. The absence of negative results in the BPC-157 literature is unusual and may reflect selective publication rather than a universally effective compound.